the safety & feasibility of PET imaging with radiolabeled 68Ga-F(ab')2-trastuzumab fragments in pts w invasive solid tumors; by using the organ/tissue & body rt dosimetry inform following i.v. injection of 68Ga-F(ab')2-trastuzumab fragments (HERScan) conclusion of study [clinicaltrials_resource:71132d75bb6a057fde27e5306ee17bb3]
Patients with invasive solid tumors
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
the safety & feasibility of PET imaging with radiolabeled 68Ga-F(ab')2-trastuzumab fragments in pts w invasive solid tumors; by using the organ/tissue & body rt dosimetry inform following i.v. injection of 68Ga-F(ab')2-trastuzumab fragments (HERScan) conclusion of study [clinicaltrials_resource:71132d75bb6a057fde27e5306ee17bb3]
Patients with invasive solid tumors
Bio2RDF identifier
71132d75bb6a057fde27e5306ee17bb3
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:71132d75bb6a057fde27e5306ee17bb3
measure [clinicaltrials_vocabulary:measure]
the safety & feasibility of PE ...... rastuzumab fragments (HERScan)
time frame [clinicaltrials_vocabulary:time-frame]
conclusion of study
description
Patients with invasive solid tumors
identifier
clinicaltrials_resource:71132d75bb6a057fde27e5306ee17bb3
title
the safety & feasibility of PE ...... (HERScan) conclusion of study
@en
type
label
the safety & feasibility of PE ...... 32d75bb6a057fde27e5306ee17bb3]
@en